On March 25th, 2025, the HPTN 104 community stakeholder consultation was held to explore the feasibility of introducing a dual prevention pill that offers protection against both pregnancy and HIV transmission for adolescent girls and young women. The consultation aimed to gather valuable insights from stakeholders, with the hope that expanding prevention options will enhance access and affordability of interventions.

This pictorial reel captures key moments from the engagement.

About the HPTN 104 Study

The HPTN 104 study is a Phase 2b, open-label, multisite clinical trial evaluating the adherence to a single daily Dual Prevention Pill (DPP) compared to a two-pill regimen (2PR) for pre-exposure prophylaxis (PrEP) and pregnancy prevention in HIV-uninfected individuals of childbearing potential.

Study Objectives:

• Primary Objective: Compare adherence to the DPP versus the two-pill regimen.

• Secondary Objectives: Assess preference, adherence during choice, persistence during choice, tolerability, side effects, and acceptability.

• Exploratory Objective: Examine facilitators and barriers of DPP adherence, acceptability, and persistence.

Study Design:

• Participants: Approximately 1,000 individuals aged 16–39 years

• Study Duration: Each participant will be involved for approximately 48 weeks.

• Study Sites: Multiple locations in sub-Saharan Africa, including Eswatini, South Africa, Uganda, and Zimbabwe.

• Study Timeline: The study commenced in April–May 2025 and is expected to conclude by mid-2026. 

Significance:

The DPP aims to simplify prevention strategies by combining HIV and pregnancy prevention into a single daily pill, potentially improving adherence and expanding prevention options for individuals at risk.

For more detailed information, you can refer to the official HPTN 104 study page at WITS RHI: HPTN 104 – Dual Prevention Pill (DPP) Study.